

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Nicardipine Hydrochloride Injection (10ml: 10mg) in form of ampoule from the National Medical Products Administration of China (the “NMPA”), being under type 4 chemical drug and regarded as passing the consistency evaluation. Nicardipine Hydrochloride Injection in form of ampoule is mainly used for emergency treatment of abnormal hypertension during surgery and for hypertensive emergencies. As stated in the Company’s announcement dated 5 March 2025, the Group’s Nicardipine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Sodium Bicarbonate Injection (10ml: 0.42g) in form of ampoule from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Sodium Bicarbonate Injection in form of ampoule is mainly used in the treatment of metabolic acidosis, alkalization of urine and intravenous intoxication by certain drugs.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 31 March 2025

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.